Daily Brief Australia: CSL Ltd, Essential Metals, Origin Energy and more

In today’s briefing:

CSL Ltd (CSL AU): Banking on Strong Growth in Immunoglobulin Franchise on Record Plasma Collection
Essential Metal: Shareholder Vote On 12th Oct. The IE Says Not Fair
(Mostly) Asia-Pac Weekly Risk Arb Wrap: Origin, United Malt, T&K Toka, Golden Eagle Energy, JMDC

CSL Ltd (CSL AU): Banking on Strong Growth in Immunoglobulin Franchise on Record Plasma Collection

CSL Ltd (CSL AU) expects strong growth in immunoglobulin franchise to continue following record plasma collections. Optimizing plasma collection costs, improving yields, and new products launches should support margin recovery.
In June 2023, first patient has received Hemgenix in the U.S. With global annual peak sales estimate of $2.4B in 2030, Hemgenix is a compelling opportunity for CSL.
CSL Seqirus is anticipated to deliver another strong year driven by demand for its differentiated products. The company began influenza vaccine shipment across the U.S. for 2023–24 influenza season.

After Mineral Resources (MIN AU) and other shareholders voted against the Tianqi Lithium JV transaction for Essential Metals (ESS AU), Develop Global (DVP AU) swooped and announced a binding Scheme.
The all-scrip Scheme transaction has the backing of MinRes, who also owns a ~12.8% stake in Develop.
The Scheme Booklet is now out. Essential shareholders vote on the transaction on the 18 October, with implementation on the 6 November. The IE opines “not fair but reasonable“.

I tally 50 – mostly firm, mostly Asia-Pac – transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.
Four new deals this week: Pact Group Holdings (PGH AU); Golden Eagle Energy (SMMT IJ); Takisawa Machine Tool (6121 JP); and JMDC (4483 JP).
Key updates took place for: Origin Energy (ORG AU), United Malt (UMG AU), Liontown Resources (LTR AU), Poly Culture (3636 HK), IMAX China Holding (1970 HK), and T&K Toka (4636 JP).

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network